Anti-CDK12 monoclonal antibody

Pre-made anti-CDK12 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to CDK12/CDK12 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T08326-Ab-1/ GM-Tg-hg-T08326-Ab-2Anti-Human CDK12 monoclonal antibodyHuman
GM-Tg-rg-T08326-Ab-1/ GM-Tg-rg-T08326-Ab-2Anti-Rat CDK12 monoclonal antibodyRat
GM-Tg-mg-T08326-Ab-1/ GM-Tg-mg-T08326-Ab-2Anti-Mouse CDK12 monoclonal antibodyMouse
GM-Tg-cynog-T08326-Ab-1/ GM-Tg-cynog-T08326-Ab-2Anti-Cynomolgus/ Rhesus macaque CDK12 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T08326-Ab-1/ GM-Tg-felg-T08326-Ab-2Anti-Feline CDK12 monoclonal antibodyFeline
GM-Tg-cang-T08326-Ab-1/ GM-Tg-cang-T08326-Ab-2Anti-Canine CDK12 monoclonal antibodyCanine
GM-Tg-bovg-T08326-Ab-1/ GM-Tg-bovg-T08326-Ab-2Anti-Bovine CDK12 monoclonal antibodyBovine
GM-Tg-equg-T08326-Ab-1/ GM-Tg-equg-T08326-Ab-2Anti-Equine CDK12 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T08326-Ab-1/ GM-Tg-hg-T08326-Ab-2; GM-Tg-rg-T08326-Ab-1/ GM-Tg-rg-T08326-Ab-2;
GM-Tg-mg-T08326-Ab-1/ GM-Tg-mg-T08326-Ab-2; GM-Tg-cynog-T08326-Ab-1/ GM-Tg-cynog-T08326-Ab-2;
GM-Tg-felg-T08326-Ab-1/ GM-Tg-felg-T08326-Ab-2; GM-Tg-cang-T08326-Ab-1/ GM-Tg-cang-T08326-Ab-2;
GM-Tg-bovg-T08326-Ab-1/ GM-Tg-bovg-T08326-Ab-2; GM-Tg-equg-T08326-Ab-1/ GM-Tg-equg-T08326-Ab-2
Products NameAnti-CDK12 monoclonal antibody
Formatmab
Target NameCDK12
Protein Sub-locationIntrocelluar Protein
Category of antibodyTherapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-CDK12 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-T08326-Ag-1Recombinant multi-species CDK12/ CRK7/ CRKR protein


    Target information

    Target IDGM-T08326
    Target NameCDK12
    Gene ID51755,69131,192350,696733,491027,101090563,511513,100068316
    Gene Symbol and Synonyms1810022J16Rik,CDK12,CRK7,CRKR,CRKRS,D11Ertd752e,Hgn,Pksc
    Uniprot AccessionQ9NYV4,Q3MJK5,E1BB50
    Uniprot Entry NameCDK12_HUMAN,CDK12_RAT,CDK12_BOVIN
    Protein Sub-locationIntrocelluar Protein
    CategoryTherapeutics Target
    DiseaseCancer
    Gene EnsemblENSG00000167258
    Target ClassificationKinase, Tumor-associated antigen (TAA)

    The target: CDK12, gene name: CDK12, also named as CRK7, CRKR, CRKRS. Enables RNA polymerase II CTD heptapeptide repeat kinase activity and cyclin binding activity. Involved in phosphorylation of RNA polymerase II C-terminal domain; protein autophosphorylation; and regulation of MAP kinase activity. Located in nuclear speck. Part of cyclin K-CDK12 complex. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.